Drugs / ACIMTAMIG
ACIMTAMIG
Trials 6
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 12 trials | ||||||
| Phase 1 | NCT02665650 | May 2016 → Jan 2019 | Hodgkins lymphoma | Affimed GmbH | Completed | No outcome recorded |
| Phase 1 | NCT01221571 | Oct 2010 → May 2013 | Hodgkins lymphoma | Affimed GmbH | Completed | No outcome recorded |
| Phase 1/22 trials | ||||||
| Phase 1/2 | NCT04074746 | Jul 2020 → Sep 2025 | B-cell non-Hodgkin lymphoma, anaplastic large cell lymphoma, classic Hodgkin lymphoma, mycosis fungoides +1 | M.D. Anderson Cancer Center | Completed | No outcome recorded |
| Phase 1/2 | NCT03192202 | Jul 2017 → Apr 2020 | primary cutaneous T-cell lymphoma | Ahmed Sawas | Completed | No outcome recorded |
| Phase 22 trials | ||||||
| Phase 2 | NCT05883449 | Oct 2023 → Nov 2024 | Hodgkins lymphoma, peripheral T-cell lymphoma, not otherwise specified | Affimed GmbH | Terminated | No outcome recorded Stop: Business |
| Phase 2 | NCT04101331 | Nov 2019 → May 2022 | mycosis fungoides variant, peripheral T-cell lymphoma, not otherwise specified | Affimed GmbH | Completed | No outcome recorded |
| Comparator or background therapy1 trial | ||||||
| Phase 2 | NCT02321592 Comparator | May 2015 → Nov 2019 | Hodgkins lymphoma | University of Cologne | Completed | No outcome recorded |
Evidence & citations 7 cited values
Every value below carries the sentence it was read from. 10 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | ACIMTAMIG | ChEMBL registry synonym — accepted as the source's own label CHEMBL5315008 ↗ |
| Known as | AFM 13 | “AFM13 is a bispecific, tetravalent chimeric antibody construct (TandAb) designed for the treatment of CD30-expressing malignancies.” PMID 25887777 ↗ Apr 2015 |
| Known as | Afm13 (anti cd30 x anti cd16) | ChEMBL registry synonym — accepted as the source's own label CHEMBL5315008 ↗ |
| Known as | Anti-cd30/cd16a monoclonal antibody afm13 | ChEMBL registry synonym — accepted as the source's own label CHEMBL5315008 ↗ |
| Action | Deplete | “AFM13-a CD30/CD16A bispecific antibody-activates natural killer (NK) cells to kill CD30+ cells.” PMID 40186077 ↗ Apr 2025 |
| Modality | Protein / enzyme biologic | “The investigational medicinal product AFM13 is a tetravalent bispecific chimeric (anti-human CD30 x anti-human CD16A) recombinant antibody construct” NCT04101331 ↗ |
| Route | Intravenous | “IV (intravenous) infusion” NCT01221571 ↗ |